859197-37-8

Basic information

• Product Name: dimethyl 2-(2-nitrobenzyl)-malonate
• Synonyms: dimethyl 2-(2-nitrobenzyl)-malonate
• CAS NO: 859197-37-8
• Molecular Weight: 267.238
• Mol File: 859197-37-8.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: dimethyl 2-(2-nitrobenzyl)-malonate(CAS DataBase Reference)
• NIST Chemistry Reference: dimethyl 2-(2-nitrobenzyl)-malonate(859197-37-8)
• EPA Substance Registry System: dimethyl 2-(2-nitrobenzyl)-malonate(859197-37-8)

Safety Data

• Hazardous Substances Data: 859197-37-8(Hazardous Substances Data)

Upstream product

• 18424-76-5 dimethyl malonate sodium salt 
• 612-23-7 2-nitrobenzyl chloride 
• 108-59-8 malonic acid dimethyl ester 
• 3958-60-9 2-nitrophenylmethyl bromide 
• 683215-25-0 (2-nitro-benzyl)-malonic acid 

Downstream Products

• 105404-33-9 (±)-methyl 2-oxo-1,2,3,4-tetrahydroquinoline-3-carboxylate 
• 2001-32-3 3-(2-nitrophenyl)propionic acid 
• 1426535-37-6 C₃₀H₃₅NO₈ 

Relevant articles and documents

NovelN-transfer reagent for converting α-amino acid derivatives to α-diazo compounds

A novel universalN-transfer reagent for direct and effective transformation of α-amino ketones, acetamides, and esters to the corresponding α-diazo products under mild basic conditions has been developed. This one-step synthetic approach not only allows for generation of α-substituted-α-diazo carbonyl compounds from α-amino acid derivatives but also permits preparation of α-diazo dipeptides fromN-terminal dipeptides (32 examples, up to 91%).

Ring Size and Substitution Effects in the Tandem Reduction-Lactamization of ortho-Substituted Nitroarenes

-

Selection, synthesis, and anti-inflammatory evaluation of the arylidene malonate derivatives as TLR4 signaling inhibitors

Inhibition of TLR4 signaling is an important therapeutic strategy for intervention in the etiology of several pro-inflammatory diseases. There has been intensive research in recent years aiming to explore this strategy, and identify small molecule inhibitors of the TLR4 pathway. However, the recent failure of a number of advanced drug candidates targeting TLR4 signaling (e.g., TAK242 and Eritoran) prompted us to continue the search for novel chemical scaffolds to inhibit this critical inflammatory response pathway. Here we report the identification of a group of new TLR4 signaling inhibitors through a cell-based screening. A series of arylidene malonate analogs were synthesized and assayed in murine macrophages for their inhibitory activity against LPS-induced nitric oxide (NO) production. The lead compound 1 (NCI126224) was found to suppress LPS-induced production of nuclear factor-kappaB (NF-κB), tumor necrosis factor (TNF-α), interleukin-1β (IL-1β), and nitric oxide (NO) in the nanomolar-low micromolar range. Taken together, this study demonstrates that 1 is a promising potential therapeutic candidate for various inflammatory diseases.